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We show that galactomannan, a polysaccharide consisting of amannose backbonewith galactose side groups present on the cell wall
of several fungi, induces a reprogramming of the inflammatory response in human macrophages through dectin-1 receptor. The
nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NF𝜅B2)/p100 was overexpressed after galactomannan challenge.
Knocking down NF𝜅B2/p100 using small interfering RNA (siRNA) indicated that NF𝜅B2/p100 expression is a crucial factor in
the progression of the galactomannan-induced refractoriness. The data presented in this study could be used as a modulator of
inflammatory response in clinical situations where refractory state is required.
1. Introduction
Galactomannan (GAL) is a component of the cell wall of
several fungi and is released during growth [1]. Detection of
GAL in blood is used to diagnose invasive fungal infections
[2, 3]. Several studies have demonstrated invasion by fungi
occurring primarily in the setting of immunosuppression
or during refractory states [4, 5]. Septic patients, with nor-
mal immune function prior Intensive Care Unit admission,
developed a refractory status and, subsequently, an invasive
pulmonary aspergillosis [6].We have generalized a refractory
state caused by the presence of bacteria whichmay lead to the
invasion of fungal infections. However, there are not data on
the potential effect of fungi invasion on themodulation of the
innate immune response.
We and others have described that lipopolysaccharide
(LPS), the major component of the outer membrane of
Gram-negative bacteria, causes monocytes/macrophages to
enter into a transient state in which they are refractory
to further endotoxin stimulation [7, 8]. This phenomenon
has been described in several clinical situations such as
sepsis where circulating cells isolated from patients show
a reduced capacity to produce proinflammatory cytokines
when stimulated with an endotoxin challenge [9, 10]. Similar
data has been reported for other pathologies such as acute
coronary syndrome [11], cystic fibrosis [12–14], and chronic
lymphocytic leukemia [15]. Previous studies from our group
and others had demonstrated the involvement of the nuclear
factor kappa-light-chain-enhancer of activated B cells 2
(NF𝜅B2)/p100 in this phenomenon [16, 17].
Here, we studied the effect of GAL on the innate response.
We hypothesized that GAL would induce a macrophage
reprogramming, leading to a refractory state.This hypothesis
was tested using an in vitromodel of human macrophages.
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2. Materials and Methods
2.1. Reagents. The following antibodies were used: anti-p100/
p52 and anti-𝛽-actin (cell signaling). The LPS from Salmo-
nella abortus was a kind gift from Dr. Galanos (Max Planck
Insitut fu¨r Immunobiologie, Freiburg, Germany). D-Galacto-
D-mannan was purchased from Sigma-Aldrich.Themedium
used for the cell culture was Dulbecco’s Modified Eagle Medium
(DMEM) from Invitrogen. Whole glucan particles (WGPs)
soluble (1,3/1.6 𝛽-glucan from S. cerevisiae) was used as dectin-
1 inhibitor activity, purchased from Invitrogen [18, 19].
2.2. Isolation, Differentiation, and Culture of Human Macro-
phages. Mononuclear cells from peripheral blood were iso-
lated from the buffy coats. The monocytes were obtained by
Ficoll/Percoll-plus gradient (GE Healthcare Bio-Sciences),
as previously described [14]. Human macrophages were
obtained by differentiation of monocytes with recombinant
human M-CSF-(Peprotech) at 50 ng/mL for 10 days. The
purity of the macrophages was tested by CD14 labeling
and flow cytometry analysis (average of 94% of CD14 pos-
itive cells). Other cell surface markers were also tested
(CD64: 75%; CD11b: 95%; see Supplementary Figure 1 avail-
able online at http://dx.doi.org/10.1155/2015/942517). All the
reagents used for the cell culture were endotoxin-free, as
assayed with the Limulus amebocyte lysate test (Cambrex).
The workflow to establish the different in vitromodels was as
indicated in each figure legend.
2.3. RNA Isolation and Quantification. The cells were washed
once with PBS and the RNA was isolated using the High
Pure RNA Isolation Kit (Roche Diagnostics). The cDNA was
obtained by reverse transcription of 1𝜇g of RNA using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems).
Gene expression levels were analyzed by real-time quan-
titative PCR (qPCR) using the Light Cycler system (Roche
Diagnostics) and cDNA obtained as described above. qPCRs
were performed using the QuantiMix Easy SYG kit from
Biotools and specific primers. Results were normalized to
the expression of the 𝛽-actin (actin), and the cDNA copy
number of each gene of interest was determined using a 7-
point standard curve as described previously [10, 11, 13, 20,
21]. The products were amplified using primers for CIITA,
5󸀠-ATT TGG CAG CAC GTG GTA CAG GA-3󸀠 (forward)
and 5󸀠-TCT GCA CAA GCT TTC CCA GG TCT T-3󸀠
(reverse), and actin, 5󸀠-GTGGGGCGCCCCAGGCACCA-
3󸀠 (forward) and 5󸀠-CTC CTT AAT GTC ACG CAC GAT
TTC-3󸀠 (reverse). All primers were synthesized, desalted, and
purified by Bonsai Biotech.
2.4. Flow Cytometer Analysis. For the surface marker stain-
ing, the cells were labeled with the following monoclonal
antibodies: anti-CD14 (Immunostep), anti-CD11b, and anti-
CD64 (BD) and HLA-DR (Immunostep). Matched isotype
antibodies were used as negative controls. The cells were
incubated in the dark for 30min at 4∘C.Thedatawas analyzed
by flow cytometry using a BD FACSCalibur flow cytometer
(BD Biosciences). The data was analyzed with Cell Quest Pro
software (BD Bioscience).
2.5. Proliferation Assay. We followed a protocol described by
Jurado-Camino et al. [15].
2.6. Cytometric Bead Array (CBA). The cytokine levels in the
culture supernatants from the human samples were deter-
mined using the CBA Flex Set (BD Biosciences) following the
manufacturer’s protocol. The data collected were analyzed by
flow cytometry using a BD FACSCalibur flow cytometer (BD
Biosciences).
2.7. Western Blot. Themonocyte cultures were harvested and
washed with ice-cold PBS containing 2mM phenylmethane-
sulfonyl fluoride and 2mM CaCl
2
(pH 7.4). Then, they were
lysed by sonication (Microson Heat System) in a solubi-
lization buffer containing protease inhibitors (200𝜇g/mL
soybean trypsin inhibitor, 1mg/mL benzamidine, 1mg/mL
aminocaproic acid, and 2mM phenylmethanesulfonyl flu-
oride) and phosphatase inhibitors (20mM Na
4
P
2
O
7
and
100mMNaF).
Proteins were measured in aliquots of cell lysates using
the Bio-Rad protein assay. Briefly, proteins were resolved
in 8% SDS-PAGE. Gels were then blotted onto nitrocellu-
lose and electrotransferred. Blots showing lanes with equal
amounts of proteins were incubated with 5% nonfat milk
in Tris buffered saline (TBS; pH 7.4) for 30min at room
temperature. Blots were then incubated overnight at 4∘Cwith
antibodies diluted in 5% nonfat milk in TBS. Antibodies
used for Western blots were rabbit anti-NF𝜅B2 p100/p52 and
anti-IRAK-M (cell signaling) 𝛽-actin (Santa Cruz Biotech-
nology, Inc.). Blots were then rinsed repeatedly in TBS
and incubated for 1 h at room temperature with alkaline
phosphatase-conjugated goat anti-rabbit IgG or goat anti-
mouse IgG secondary antibodies diluted in 5% nonfat milk
in TBS. After rinsing with TBS, blots were incubated with the
alkaline phosphatase substrate (5-bromo-4-chloro-3-indolyl
phosphate/nitroblue tetrazolium tablets; Sigma-Aldrich).
2.8. Small Interfering RNA (siRNA). Life Technologies
designed and synthesized the NF𝜅B2 (p100) and the control
siRNAs. The monocytes were transfected with siRNAs using
the AmaxaNucleofector system (Amaxa Biosystems). Briefly,
1 × 106 monocytes, mixed with 25 𝜇M of siRNA in 100 𝜇L of
transfection buffer, were transferred to an electroporation
cuvette and nucleofected according to the manufacturer’s
instructions.The cells were then immediately transferred into
a 6-well culture plate (Costar) containing 2mL of prewarmed
RPMImedium supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen). The nucleofected cells were
cultured at 37∘C with 5% CO
2
for 1 h before the assays.
2.9. Statistical Analysis. Thenumber of experiments analyzed
is indicated in each figure legend. The data were collected
from a minimum of three experiments and are expressed as
mean ± SD. The statistical significance was calculated using
paired 𝑡-test. The statistical significance was set at 𝑝 < 0.05
and all statistical analyses were conducted using Prism 5.0
software (GraphPad).
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Figure 1: Galactomannan (GAL) attenuates the LPS-induced inflammation in human macrophages. (a) Schematic representation of the ET
model used for this study. The cultures of human macrophages were or not pretreated with 10 ng/mL LPS or 10𝜇g/mL GAL for 24 h, washed
twice with PBS, cultured in medium for 16 h, and restimulated with 10 ng/mL LPS for the indicated times. Supernatants were harvested at
the indicated times (3 h, 5 h, and 24 h) and TNF𝛼 (b), IL6 (c), and IL10 (d) proteins levels were evaluated by CBA (𝑛 = 5); ∗𝑝 < 0.05,
∗∗
𝑝 < 0.01 comparing GAL + LPS with LPS. (e) Cell surface expression of HLA-DR was analyzed by flow cytometry. (𝑛 = 5), ∗𝑝 < 0.05,
comparing GAL + LPS with LPS 24 h. (f) Total mRNA was isolated from cells, cDNA was synthesized and CIITA real-time quantitative
PCR was performed. (𝑛 = 4), ∗𝑝 < 0.05 comparing GAL + LPS with LPS 24 h. (g) Human heterologous lymphocytes were labeled with the
membrane stain PKH2 Green Fluorescent Cell Linker Kit (Sigma-Aldrich) and cocultured with LPS, LPS + LPS, or GAL + LPS macrophages
for 5 days. Lymphocyte proliferation was measured as a loss of green fluorescence intensity in the CD3+ gate, for this analysis. The fold
induction is shown. ∗𝑝 < 0.05, comparing GAL + LPS with LPS.
3. Results
3.1. Galactomannan (GAL) Inhibited the LPS-Induced Inflam-
mation in Human Macrophages. It is well accepted that
human monocytes and macrophages (MΦs) preconditioned
with endotoxins, mitochondrial Danger Associated Molec-
ular Patterns (DAMPs), or some tumor cells are unable to
orchestrate a classic inflammatory response once they are
challenged with LPS [8, 14, 15, 22]. To study the potential
role of GAL as regulator of inflammation, human MΦs were
exposed to 10 𝜇g of GALfor 24 h [4]. Next, cultures were
washed, maintained in complete medium, and challenged
with 10 ng/mL of LPS (see scheme in Figure 1(a) and cell
purity in Supplemental Figure 1A). Note that, GAL was
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checked by LAL (Limulus amebocyte lysate) test to rule out
endotoxin contamination (data not shown). As LPS prestim-
ulation, GAL impeded the production of proinflammatory
cytokines in a second stimulation with LPS (Figures 1(b)
and 1(c)). Remarkably, IL10, a well-known anti-inflammatory
cytokine, is also downregulated (Figure 1(d)). The expression
and regulation of IL10 are controversial in this context.
Several authors have shown that IL10 plays a crucial role in
ET control, whereas others have reported aweak effect of IL10
in sepsis-induced tolerance [8]. In addition, IL10 knockout
mice reproduced an ET phenotype when they were exposed
twice to LPS [23]. Another feature of ET, such as HLA
downregulation, was also observed (Figure 1(e)). In addition,
GAL pretreatment downregulated the expression of HLA-
DR. In this case, we also confirmed a patent reduction of the
HLA-II master regulator gene, CIITA (Figure 1(f)). Finally,
we verified the functional impact of MHC class II down-
regulation via a lymphocyte-proliferation assay (Figure 1(g)).
The inhibitory effect is abolished after 5 days (Supplemental
Figure 2).
3.2. Galactomannan Did Not Induce an Inflammatory
Response in Human Macrophages. Once we established
that GAL induces a refractoriness state in human MΦs, we
sought to understand the bases of this phenomenon. We
test the effect of GAL on cultures of humans MΦs (see the
experimental design in Figure 2(a)). GAL did not provoke a
strong inflammatory response in these cells (Figures 2(b)–
2(d)). Remarkably, mitochondrial DAMPs, such as mtDNA,
do not induce a manifest inflammatory response in human
monocytes but rather a refractory status [24]. Notably, an
increase in the dose of GAL had no significant effect on
the production of TNF𝛼 and other cytokines (Figure 2(e)
and data not shown), and cell viability was not affected
(Figure 2(f)).
3.3. NF𝜅B2/p100 Is Overexpressed in Human Macrophages
after Galactomannan Challenge. A number of previous stud-
ies indicate that disruption of the classical NF𝜅B2 path-
way is closely involved in the control of inflammation [7].
Many molecules have been studied and postulated to be the
main regulators in this regard such as IRAK-M and, more
recently, NF𝜅B2/p100 [11, 25, 26]. However, in ourmodel only
NF𝜅B2/p100 was overexpressed after GAL challenge (Figures
3(a) and 3(b)). In contrast to NF𝜅B2/p100, the Western blot
analysis indicated that GAL did not increase the basal levels
of the pseudokinase IRAK-M (Figures 3(c) and 3(d)).
3.4. Dectin-1 Mediates Macrophage Recognition of GAL.
Dectin-1 is mainly membrane-bound receptor that recog-
nizes polysaccharide structures. We hypothesized that GAL
might be recognized by dectin-1. A well-known dectin-1
receptor inhibitor (WGPs) was added simultaneously with
GAL (Figure 4(a)). GAL impeded the production of proin-
flammatory cytokines in a second stimulation with LPS
whereas the WGPs revert this tolerant state (Figures 4(b)–
4(d)). In addition,NF𝜅B2/p100 is not overexpressed using the
WGPs only in GAL stimulation (Figures 4(e) and 4(f)). This
data could indicate that dectin-1 modulates TLR pathway by
NF𝜅B2/p100. A collaborative induction and trigger modula-
tions of inflammatory responses by these two pathways are
reported [27–30].
3.5. Specific NF𝜅B2/p100 Downregulation Reverts the Refrac-
toriness Induced by Galactomannan. To study the impact
of NF𝜅B2/p100 on GAL-induced ET status, we knocked
NF𝜅B2/p100 down using siRNA.The humanmonocytes were
transfectedwith a siRNA forNF𝜅B2/p100 (siRp100) or siRNA
control (siRcontrol) as a negative control. In siRcontrol-
transfected cells, NF𝜅B2/p100 induction was observed after
LPS or Gal challenge for 24 hours, whereas siRp100-
transfected cells abolished the induction (Figure 5(a)). The
siRp100-transfected cells recover the TNF𝛼 production when
the cells were pretreated with LPS and GAL (Figure 5(b)).
Other cytokines were tested with similar results (data not
shown).
4. Discussion
Several previous studies have demonstrated that two consec-
utive LPS treatments separated in time reduced significantly
the inflammatory response in the second challenge [7, 8,
14]. This phenomenon has been also described in patients
that suffered from sepsis, acute coronary syndrome (ACS),
and chronic lymphocytic leukemia (CLL), in which their
circulating cells were unable to produce inflammation after
an ex vivo endotoxin challenge [15, 24, 31]. While in sepsis
patients were previously exposed to bacterial endotoxins,
in ACS and CLL these patients were endotoxin-free. In
these last pathologies mitochondrial DAMPS and tumor cells
were responsible for the refractoriness observed, respectively.
These data suggested that not only endotoxins are able to
provoke a refractory state of the human innate immune
cells. Additionally, the clinical experience in Intensive Care
Units revealed a putative correlation between an invasive
pulmonary Aspergillosis spp. and a refractory state in septic
patients [6]. In this regard we explore the effect of galac-
tomannan as a potential regulator of inflammation.
Data present here indicate that although GAL did not
induce any inflammatory response, this polysaccharide is able
to reprogram human monocytes and it reduces the inflam-
mation induced by LPS. GAL affected not only cytokine
production but also HLA-DR expression. This well-known
MHCII member has been reported as essential for the
switch to the adaptive response and it is downregulated in
septic patients during the immunosuppression phase [32–35].
Moreover, we also reported a patent regulation of the master
regulator CIITA [14, 36], being the reason by which HLA-DR
expression was reduced.
A key role for dectin-1 in the response to some fungal
infections was first demonstrated by the finding that dectin-
1 knockout mice are more susceptible to infection with
Candida albicans or Aspergillus fumigates [37, 38]. TLRs
and dectin-1 can activate both NF𝜅B2 and MAPK cascades.
However, they signal through an ITAM-like motif in their
cytoplasmic domain, which recruits the tyrosine kinase Syk
and RAF proto-oncogene serine/threonine-protein kinase
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Figure 2: GAL is not able to induce an inflammatory response. (a) Schematic representation of the model used for this study.The cultures of
human macrophages were treated with 10 ng/mL LPS or 10𝜇g/mL GAL for 24 h. The controls were not treated. Supernatants were harvested
and TNF𝛼 (b), IL6 (c), and IL-10 (d) proteins levels were evaluated by CBA (𝑛 = 6); ∗𝑝 < 0.05, ∗∗𝑝 < 0.01 compared with LPS. (e)The culture
of human macrophages was treated with GAL at various concentrations for 24 h. Supernatants were harvested and the TNF𝛼 protein levels
were evaluated by CBA (𝑛 = 3). (f) The culture of human macrophages was treated with GAL at various concentrations for 24 h. Cells were
harvested, and intracellular cells stained with 7AAD were analyzed by flow cytometry. The 7AAD negative cells are represented (percentage
of cell viability, 𝑛 = 4).
to activate downstream signaling [39–41]. Moreover, in
macrophages and dendritic cells dectin-1 and TLR are syn-
ergistic in mediating production of cytokines [30, 42]. Our
data suggest that GAL recognition by dectin-1 receptor in
macrophages attenuates the inflammation response.
A number of molecular mechanisms have been impli-
cated in the control of inflammation after endotoxin chal-
lenge [7]. The activation of the pseudokinase IRAK-M has
been described as essential to control the intracellular inflam-
matory pathway [26, 43–46]. However, our data did not
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Figure 3:TheNF𝜅B2/p100 accumulation after the first LPS orGAL challenge. Cultures of humanmacrophageswere challengedwith 10 ng/mL
LPS or 10𝜇g/mL GAL for 24 h. The controls were not treated. The levels of NF𝜅B2/p100 or IRAK-M and 𝛽-actin were studied by Western
blot analysis of the cytosolic fraction. (a) A NF𝜅B2/p100 standard blot is shown (𝑛 = 6). (b) Densitometry analysis: arbitrary units [AU] of
NF𝜅B2/p100 bands are normalized with respect to 𝛽-actin (𝑛 = 6). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01 compared with LPS. (c) A IRAK-M standard blot
is shown (𝑛 = 3). (d) Densitometry analysis: arbitrary units [AU] of IRAK-M bands are normalized with respect to 𝛽-actin (𝑛 = 3).
indicate a role for IRAK-M in the observed GAL-induced
inhibition of inflammation. In contrast, a patent expression of
NF𝜅B2/p100 was detected after GAL treatment.Thismember
of the noncanonical pathway exhibits inhibitory properties
on the canonical pathway [47]. In this regard, NF𝜅B2/p100
could be considered as a fourth IkB protein, sequestering
latentNF𝜅B2dimers [47].Our results demonstrated that after
blocking the main GAL receptor, dectin-1, the expression of
NF𝜅B2/p100 was also reduced. Moreover, knocking down
assays indicated that the expression of NF𝜅B2/p100 was
mandatory in the studied context.
In conclusion, the data presented in this study indicate
that galactomannan could be used as a controller of the
inflammatory responses in some clinical situations. Curi-
ously, its effect did not involve a previous inflammation.These
results indicate that the presence of GAL and, subsequently,
fungi contamination could lead to a refractory state in
patients. Our data also indicated that galactomannan acts
through dectin-1 and NF𝜅B2/p100 plays a pivotal role in its
refractory state.
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Figure 4: GAL is mediated by dectin-1 receptor. (a) Schematic representation of the inhibitor receptor of GAL model used for this study.
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Proteins levels were evaluated by CBA (𝑛 = 4); ∗𝑝 < 0.05 compared with LPS. Levels of NF𝜅B2/p100 and 𝛽-actin were studied by Western
blot analysis of the cytosolic fraction. (e) A NF𝜅B2/p100 standard blot is shown (𝑛 = 3). (f) Densitometry analysis: arbitrary units [AU] of
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8 Mediators of Inflammation
LPSControl GAL GALLPS
siRcontrol siRp100
𝛽-actin
NF𝜅B2/p100
(a)
Co
nt
ro
l
LP
S
LP
S 
+ 
LP
S
G
A
L 
+ 
LP
S
Co
nt
ro
l
LP
S
LP
S 
+ 
LP
S
G
A
L 
+ 
LP
S
0
1000
2000
3000
4000
siRcontrol siRp100
TN
F𝛼
(p
g/
m
L)
∗∗
∗
(b)
Figure 5: The attenuated inflammation effect induced by GAL
is reverted by small interfering RNA of NF𝜅B2/p100. Cultures of
siRp100 and sirRcontrol transfected humanmonocyte/macrophages
were treated with 10 g/mL GAL or 10 ng/mL LPS for 24 h. The
controls were not treated. The levels of NF𝜅B2/p100 and 𝛽-actin
were studied byWestern blot analysis of the cytosolic fraction. (a) A
NF𝜅B2/p100 and 𝛽-actin standard blot are shown (𝑛 = 5). (b) TNF
protein level was evaluated by CBA (𝑛 = 4); ∗𝑝 < 0.05, ∗∗𝑝 < 0.01
compared with siRcontrol.
Acknowledgments
The authors would like to thank Ms. Aurora Mun˜oz for her
technical assistance and ServingMed.com for the editing of
the paper. They would also like to acknowledge the Fondo de
Investigacio´n Sanitaria grant awarded to ELC.
References
[1] S. M. Bowman and S. J. Free, “The structure and synthesis of the
fungal cell wall,” BioEssays, vol. 28, no. 8, pp. 799–808, 2006.
[2] K. C. M. C. Pedroza, S. B. de Matos, D. L. de Moura et al.,
“Reproducibility of positive results for the detection of serum
galactomannan by Platelia Aspergillus EIA,” Mycopathologia,
vol. 176, no. 3-4, pp. 295–297, 2013.
[3] D. Fischer, L. Van Waeyenberghe, C. Cray et al., “Comparison
of diagnostic tools for the detection of aspergillosis in blood
samples of experimentally infected falcons,”Avian Diseases, vol.
58, no. 4, pp. 587–598, 2014.
[4] L. Y. A. Chai, A. G. Vonk, B. J. Kullberg et al., “Aspergillus
fumigatus cell wall components differentially modulate host
TLR2 and TLR4 responses,”Microbes and Infection, vol. 13, no.
2, pp. 151–159, 2011.
[5] G.M.Gersuk, D.M.Underhill, L. Zhu, andK. A.Marr, “Dectin-
1 and TLRs permit macrophages to distinguish between dif-
ferent Aspergillus fumigatus cellular states,” The Journal of
Immunology, vol. 176, no. 6, pp. 3717–3724, 2006.
[6] F. A´lvarez Lerma, P. Olaechea Astigarraga, M. Palomar
Mart´ınez et al., “Respiratory infections caused by Aspergillus
spp. in critically ill patients admitted to the intensive care units,”
Medicina Intensiva, vol. 39, no. 3, pp. 149–159, 2015.
[7] S. K. Biswas and E. Lopez-Collazo, “Endotoxin tolerance: new
mechanisms, molecules and clinical significance,” Trends in
Immunology, vol. 30, no. 10, pp. 475–487, 2009.
[8] E. Lo´pez-Collazo and C. Del Fresno, “Pathophysiology of
endotoxin tolerance: mechanisms and clinical consequences,”
Critical Care, vol. 17, article 242, 2013.
[9] M.M. Faas, H.Moes, J.W. Fijen, A. C.M. Kobold, J. E. Tulleken,
and J. G. Zijlstra, “Monocyte intracellular cytokine production
during human endotoxaemia with or without a second in
vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase
inhibitor, on LPS-hyporesponsiveness,”Clinical & Experimental
Immunology, vol. 127, no. 2, pp. 337–343, 2002.
[10] P. Escoll, C. del Fresno, L. Garc´ıa et al., “Rapid up-regulation
of IRAK-M expression following a second endotoxin challenge
in human monocytes and in monocytes isolated from septic
patients,” Biochemical and Biophysical Research Communica-
tions, vol. 311, no. 2, pp. 465–472, 2003.
[11] C. del Fresno, L. Soler-Rangel, A. Soares-Schanoski et al.,
“Inflammatory responses associated with acute coronary syn-
drome up-regulate IRAK-M and induce endotoxin tolerance in
circulating monocytes,” Journal of Endotoxin Research, vol. 13,
no. 1, pp. 39–52, 2007.
[12] R. del Campo, E. Mart´ınez, C. del Fresno et al., “Translocated
LPS might cause endotoxin tolerance in circulating monocytes
of cystic fibrosis patients,” PLoS ONE, vol. 6, no. 12, Article ID
e29577, 2011.
[13] C. del Fresno, V. Go´mez-Pin˜a, V. Lores et al., “Monocytes from
cystic fibrosis patients are locked in an LPS tolerance state:
down-regulation of TREM-1 as putative underlying mecha-
nism,” PLoS ONE, vol. 3, no. 7, Article ID e2667, 2008.
[14] C. del Fresno, F. Garcia-Rio, V. Gomez-Pina et al., “Potent
phagocytic activity with impaired antigen presentation identi-
fying lipopolysaccharide-tolerant human monocytes: demon-
stration in isolatedmonocytes from cystic fibrosis patients,”The
Journal of Immunology, vol. 182, pp. 6494–6507, 2009.
[15] T. Jurado-Camino, R. Co´rdoba, L. Esteban-Burgos et al.,
“Chronic lymphocytic leukemia: a paradigm of innate immune
cross-tolerance,” Journal of Immunology, vol. 194, no. 2, pp. 719–
727, 2015.
[16] H. deWit,W.H.A.Dokter, S. B. Koopmans et al., “Regulation of
p100 (NFKB2) expression in human monocytes in response to
inflammatory mediators and lymphokines,” Leukemia, vol. 12,
no. 3, pp. 363–370, 1998.
[17] C. Cubillos-Zapata, E. Herna´ndez-Jime´nez, V. Toledano et al.,
“NF𝜅B2/p100 is a key factor for endotoxin tolerance in human
monocytes: a demonstration using primary human monocytes
from patients with sepsis,” Journal of Immunology, vol. 193, no.
8, pp. 4195–4202, 2014.
Mediators of Inflammation 9
[18] H. S. Goodridge, C. N. Reyes, C. A. Becker et al., “Activation
of the innate immune receptor Dectin-1 upon formation of a
‘phagocytic synapse’,” Nature, vol. 472, no. 7344, pp. 471–475,
2011.
[19] E. L. Adams, P. J. Rice, B. Graves et al., “Differential high-
affinity interaction of dectin-1 with natural or synthetic glucans
is dependent upon primary structure and is influenced by
polymer chain length and side-chain branching,” The Journal
of Pharmacology and Experimental Therapeutics, vol. 325, no. 1,
pp. 115–123, 2008.
[20] C. del Fresno, K. Otero, L. Go´mez-Garc´ıa et al., “Tumor cells
deactivate human monocytes by up-regulating IL-1 receptor
associated kinase-M expression via CD44 and TLR4,” The
Journal of Immunology, vol. 174, no. 5, pp. 3032–3040, 2005.
[21] V. Go´mez-Pin˜a, A. Soares-Schanoski, A. Rodr´ıguez-Rojas
et al., “Metalloproteinases shed TREM-1 ectodomain from
lipopolysaccharide-stimulated human monocytes,” Journal of
Immunology, vol. 179, no. 6, pp. 4065–4073, 2007.
[22] A. Soares-Schanoski, T. Jurado, R. Co´rdoba et al., “Impaired
antigen presentation and potent phagocytic activity identifying
tumor-tolerant human monocytes,” Biochemical and Biophysi-
cal Research Communications, vol. 423, no. 2, pp. 331–337, 2012.
[23] F. Randow, U. Syrbe, C. Meisel et al., “Mechanism of endotoxin
desensitization: involvement of interleukin 10 and transforming
growth factor 𝛽,” Journal of Experimental Medicine, vol. 181, no.
5, pp. 1887–1892, 1995.
[24] I. Ferna´ndez-Ruiz, F. Arnalich, C. Cubillos-Zapata et al., “Mito-
chondrial DAMPs induce endotoxin tolerance in humanmono-
cytes: an observation in patients with myocardial infarction,”
PLoS ONE, vol. 9, no. 5, Article ID e95073, 2014.
[25] Y. Xiong andA. E.Medvedev, “Induction of endotoxin tolerance
in vivo inhibits activation of IRAK4 and increases negative
regulators IRAK-M, SHIP-1, and A20,” Journal of Leukocyte
Biology, vol. 90, no. 6, pp. 1141–1148, 2011.
[26] K. Kobayashi, L. D. Hernandez, J. E. Gala´n, C. A. Janeway Jr., R.
Medzhitov, and R. A. Flavell, “IRAK-M is a negative regulator
of Toll-like receptor signaling,” Cell, vol. 110, no. 2, pp. 191–202,
2002.
[27] H. S. Goodridge, A. J. Wolf, and D. M. Underhill, “Beta-glucan
recognition by the innate immune system,” Immunological
Reviews, vol. 230, no. 1, pp. 38–50, 2009.
[28] A. M. Kerrigan and G. D. Brown, “Syk-coupled C-type lectin
receptors that mediate cellular activation via single tyrosine
based activation motifs,” Immunological Reviews, vol. 234, no.
1, pp. 335–352, 2010.
[29] K.M.Dennehy, G. Ferwerda, I. Faro-Trindade et al., “Syk kinase
is required for collaborative cytokine production induced
through dectin-1 and Toll-like receptors,” European Journal of
Immunology, vol. 38, no. 2, pp. 500–506, 2008.
[30] B. N. Gantner, R. M. Simmons, S. J. Canavera, S. Akira, and
D. M. Underhill, “Collaborative induction of inflammatory
responses by dectin-1 and toll-like receptor 2,” Journal of
Experimental Medicine, vol. 197, no. 9, pp. 1107–1117, 2003.
[31] E. Lo´pez-Collazo, V. Go´mez-Pin˜a, and F. Arnalich, “Under-
standing immune dysfunctions in sepsis patients,”Critical Care,
vol. 14, no. 4, article 435, 2010.
[32] M. P. Hernandez-Fuentes, A. N. Warrens, and R. I. Lechler,
“Immunologic monitoring,” Immunological Reviews, vol. 196,
pp. 247–264, 2003.
[33] K. Wolk, S. Kunz, N. E. A. Crompton, H.-D. Volk, and R. Sabat,
“Multiple mechanisms of reduced major histocompatibility
complex class II expression in endotoxin tolerance,” Journal of
Biological Chemistry, vol. 278, no. 20, pp. 18030–18036, 2003.
[34] K. Wolk, W.-D. Do¨cke, V. von Baehr, H.-D. Volk, and R. Sabat,
“Impaired antigen presentation by human monocytes during
endotoxin tolerance,” Blood, vol. 96, no. 1, pp. 218–223, 2000.
[35] A. B. Adams, T. C. Pearson, and C. P. Larsen, “Heterologous
immunity: an overlooked barrier to tolerance,” Immunological
Reviews, vol. 196, pp. 147–160, 2003.
[36] G. Monneret, M.-E. Finck, F. Venet et al., “The anti-inflam-
matory response dominates after septic shock: association of
low monocyte HLA-DR expression and high interleukin-10
concentration,” Immunology Letters, vol. 95, no. 2, pp. 193–198,
2004.
[37] J. L. Werner, A. E. Metz, D. Horn et al., “Requisite role for
the dectin-1 beta-glucan receptor in pulmonary defense against
Aspergillus fumigatus,”The Journal of Immunology, vol. 182, no.
8, pp. 4938–4946, 2009.
[38] P. R. Taylor, S. V. Tsoni, J. A. Willment et al., “Dectin-1 is
required for 𝛽-glucan recognition and control of fungal infec-
tion,” Nature Immunology, vol. 8, no. 1, pp. 31–38, 2007.
[39] S. I. Gringhuis, J. denDunnen,M. Litjens et al., “Dectin-1 directs
T helper cell differentiation by controlling noncanonical NF-𝜅B
activation through Raf-1 and Syk,” Nature Immunology, vol. 10,
no. 2, pp. 203–213, 2009.
[40] D. M. Underhill, “Collaboration between the innate immune
receptors dectin-1, TLRs, and Nods,” Immunological Reviews,
vol. 219, no. 1, pp. 75–87, 2007.
[41] D. M. Reid, N. A. Gow, and G. D. Brown, “Pattern recognition:
recent insights from dectin-1,” Current Opinion in Immunology,
vol. 21, no. 1, pp. 30–37, 2009.
[42] Y. Sobanov, A. Bernreiter, S. Derdak et al., “A novel cluster of
lectin-like receptor genes expressed inmonocytic, dendritic and
endothelial cells maps close to the NK receptor genes in the
human NK gene complex,” European Journal of Immunology,
vol. 31, no. 12, pp. 3493–3503, 2001.
[43] L. M. Sly, M. J. Rauh, J. Kalesnikoff, C. H. Song, and G. Krystal,
“LPS-induced upregulation of SHIP is essential for endotoxin
tolerance,” Immunity, vol. 21, no. 2, pp. 227–239, 2004.
[44] B. Beutler, “SHIP, TGF-𝛽, and endotoxin tolerance,” Immunity,
vol. 21, no. 2, pp. 134–135, 2004.
[45] C. van’t Veer, P. S. van den Pangaart, M. A. D. van Zoelen et
al., “Induction of IRAK-M is associatedwith lipopolysaccharide
tolerance in a human endotoxemia model,” The Journal of
Immunology, vol. 179, no. 10, pp. 7110–7120, 2007.
[46] W. J. Wiersinga, C. van’t Veer, P. S. van den Pangaart et al.,
“Immunosuppression associated with interleukin-1R-associ-
ated-kinase-M upregulation predicts mortality in Gram-nega-
tive sepsis (melioidosis),” Critical Care Medicine, vol. 37, no. 2,
pp. 569–576, 2009.
[47] S. Basak, H. Kim, J. D. Kearns et al., “A fourth I𝜅B protein within
the NF-𝜅B signaling module,” Cell, vol. 128, no. 2, pp. 369–381,
2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
